Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 8/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | IDH2 | P48735 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15102388 | 0.93 | KCNH3 (0.55) | KCNH3JAK2JAK3CA1CA2 | |
| SCHEMBL29763287 | 0.87 | CA1 (0.60) | KCNH3CA1CA2CA9CTSK | |
| SCHEMBL15102261 | 0.87 | CA1 (0.60) | KCNH3CA1CA2CA9CTSK | |
| SCHEMBL16392015 | 0.84 | ABCG2 (0.57) | JAK2JAK3PTGS2KDM4EMEN1 | |
| SCHEMBL29560743 | 0.83 | KCNH3 (0.53) | KCNH3CA1CA2CA9CTSK | |
| SCHEMBL15102602 | 0.83 | KCNH3 (0.53) | KCNH3CA1CA2CA9CTSK | |
| SCHEMBL15102555 | 0.82 | IDH1 (0.69) | SYKIDH2IDH1 | |
| SCHEMBL15102338 | 0.82 | KCNH3 (0.81) | KCNH3CA1CA2CA9CTSK | |
| SCHEMBL19486673 | 0.82 | KCNH3 (0.81) | KCNH3CA1CA2CA9CTSK | |
| SCHEMBL15102564 | 0.82 | KCNH3 (0.52) | KCNH3CA1CA2CA9CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| EP-2800743-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-19 | — | — | US | disclosed |
| US-9732062-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732062-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9656999-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102431-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, MMP8 | KCNH3 4664/4885JAK2 2233/4885JAK3 3820/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885JAK2 1396/4885JAK3 3804/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | KCNH3 4722/4885JAK2 1396/4885JAK3 3804/4885 |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885JAK2 1396/4885JAK3 3804/4885 |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885JAK2 1396/4885JAK3 3804/4885 |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885JAK2 1396/4885JAK3 3804/4885 |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | KCNH3 4722/4885JAK2 1396/4885JAK3 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.